Rafael Holdings Inc (RFL)

$1.35 +0.02 (1.50%)
Market Cap 69.70M
Revenue (ttm) 920,000.00
Net Income (ttm) -30.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,317.39%
Debt to Equity Ratio 0.01
Volume 117,511
Avg Vol 77,936
Day's Range N/A - N/A
Shares Out 52.01M
Stochastic %K 73%
Beta 0.50
Analysts Strong Buy
Price Target N/A

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for t...

Industry: Real Estate Services
Sector: Real Estate
Phone: 212 658 1450
Address:
520 Broad Street, Newark, United States
Moksi
Moksi May. 13 at 6:17 PM
$RFL x15x20
0 · Reply
Biotechnicity
Biotechnicity May. 13 at 4:36 PM
$ZVRA Very interesting time here both for Zevra and the NPC treatment space. We have the EU decision — a market 33% larger than the U.S. but with reasonable drug pricing which makes it about as valuable. The decision has not come early and could be hampered by some patient reports of difficulty breathing. Still maths well if we look at the historical precedent of rubber stamping FDA approvals but the luster and integrity of that organization has faltered and nations are each looking after their own best interests. Approving U.S. drugs in European markets is no longer a given. I suspect future approvals in Europe will require big pharma clout or be obviously efficacious and low on side effects. Is MIPLYFFA either of those? Another reason that the price remains fixed here is the Phase-3 trial about to read out at $RFL. No expectation of success but that isn’t necessary to attain approval. The injectable version failed but has been resubmitted for approval recently. Aware of that? GL
3 · Reply
Moksi
Moksi May. 13 at 1:47 PM
$RFL let’s blow this up
0 · Reply
Biotechnicity
Biotechnicity May. 11 at 4:34 PM
$RFL Also, with respect to Zevra, the EU decision on MIPLYFFA is coming within 6-weeks time and could be any day now. If approved, ZVRA jumps. If declined, another door opens to Cyclo/RFL. In fact, a CHMP no is a huge step in favor of ultimate approval in Europe right here if there’s significant benefit. If.
0 · Reply
Aye_Sir
Aye_Sir May. 11 at 1:19 PM
$RFL lets make some $
0 · Reply
Biotechnicity
Biotechnicity May. 11 at 5:15 AM
$RFL One sign I’m keeping an eye on is the potential sale of Zevra (ZVRA) in the very near future. I say this because tute holdings are growing and retail shares so tight that small orders ratchet up their price in AH (at that M-C no small feat). If Zevra is sold before our results come in the purchaser will have to know that there’s no competition to their profit on the near horizon. A possible study fail flag. However, if the sale of Zevra is delayed until after our results are released, it could be a sign that pending competition needs to be swallowed first. A possible checkerboard flag. In either scenario, Zevra gets sold. Not a bad buy over there. Here, 🤦
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 May. 8 at 5:24 PM
$FLNA SAVA is dead. Cyclo is now officially a better asset! It was only a matter of time.. come join $RFL before our readout this summer!!
1 · Reply
CaseOfTheYips1
CaseOfTheYips1 May. 8 at 5:21 PM
$RFL been waiting for this day… Our sp has surpassed sava! Congratulations on us being better than that dumpster fire.
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 May. 8 at 12:27 AM
$RFL One of the things I would like to see in the next six weeks is advertising for production and commercialization positions. Maybe a few sales people. That would be a good indicator that they have high confidence. If anybody can monitor their employment page, that would be helpful.
1 · Reply
Biotechnicity
Biotechnicity May. 7 at 6:04 PM
$RFL According to StockTwits own summation, Zevra is reporting that MIPLYFFA is causing “hypersensitivity reactions” (a known issue in previous studies regarding breathing through the nose). The stock is down 6% and the door to Cyclo opens wider while the jump height on P-3 success expands higher.
0 · Reply
Latest News on RFL
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Mar 16, 2026, 4:01 PM EDT - 2 months ago

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Dec 11, 2025, 4:01 PM EST - 5 months ago

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Oct 29, 2025, 4:24 PM EDT - 7 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Oct 28, 2025, 4:01 PM EDT - 7 months ago

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Sep 16, 2025, 8:00 AM EDT - 8 months ago

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Rafael announces continuation of Phase 3 TransportNPC study following DMC review

2025-06-18T11:10:50.000Z - 11 months ago

Rafael announces continuation of Phase 3 TransportNPC study following DMC review

Rafael Holdings reports Q3 EPS (19c) vs ($1.36) last year

2025-06-11T11:05:50.000Z - 1 year ago

Rafael Holdings reports Q3 EPS (19c) vs ($1.36) last year

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Jun 4, 2025, 4:01 PM EDT - 1 year ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 20, 2025, 4:01 PM EDT - 1 year ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael announces revised subscription rights in connection with offering

2025-05-05T11:21:47.000Z - 1 year ago

Rafael announces revised subscription rights in connection with offering

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 1 year ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 1 year ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 26, 2025, 6:50 AM EDT - 1 year ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Mar 13, 2025, 5:50 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

Feb 20, 2025, 4:35 PM EST - 1 year ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Rafael Holdings reports Q1 EPS (37c) vs (15c) last year

2024-12-11T12:06:09.000Z - 1 year ago

Rafael Holdings reports Q1 EPS (37c) vs (15c) last year

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Dec 11, 2024, 7:00 AM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Nov 6, 2024, 7:14 PM EST - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

Oct 2, 2024, 12:00 PM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Rafael Holdings, Cyclo Therapeutics enter merger agreement

2024-08-22T10:52:19.000Z - 1 year ago

Rafael Holdings, Cyclo Therapeutics enter merger agreement

CYTH

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Jun 14, 2024, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Oct 30, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Aug 2, 2023, 8:16 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 13, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Jun 5, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

May 2, 2023, 8:12 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Rafael Holdings announces up to $5M share repurchase program

2023-04-04T12:22:42.000Z - 3 years ago

Rafael Holdings announces up to $5M share repurchase program

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Mar 14, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Rafael Holdings reports Q1 EPS (22c) vs. ($5.88) last year

2022-12-13T12:21:32.000Z - 3 years ago

Rafael Holdings reports Q1 EPS (22c) vs. ($5.88) last year

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Nov 15, 2022, 4:01 PM EST - 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Oct 31, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Aug 23, 2022, 7:43 AM EDT - 4 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jul 6, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 2:14 PM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 16, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 14, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

May 24, 2022, 11:04 AM EDT - 4 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 17, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 11, 2022, 4:00 PM EST - 4 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Moksi
Moksi May. 13 at 6:17 PM
$RFL x15x20
0 · Reply
Biotechnicity
Biotechnicity May. 13 at 4:36 PM
$ZVRA Very interesting time here both for Zevra and the NPC treatment space. We have the EU decision — a market 33% larger than the U.S. but with reasonable drug pricing which makes it about as valuable. The decision has not come early and could be hampered by some patient reports of difficulty breathing. Still maths well if we look at the historical precedent of rubber stamping FDA approvals but the luster and integrity of that organization has faltered and nations are each looking after their own best interests. Approving U.S. drugs in European markets is no longer a given. I suspect future approvals in Europe will require big pharma clout or be obviously efficacious and low on side effects. Is MIPLYFFA either of those? Another reason that the price remains fixed here is the Phase-3 trial about to read out at $RFL. No expectation of success but that isn’t necessary to attain approval. The injectable version failed but has been resubmitted for approval recently. Aware of that? GL
3 · Reply
Moksi
Moksi May. 13 at 1:47 PM
$RFL let’s blow this up
0 · Reply
Biotechnicity
Biotechnicity May. 11 at 4:34 PM
$RFL Also, with respect to Zevra, the EU decision on MIPLYFFA is coming within 6-weeks time and could be any day now. If approved, ZVRA jumps. If declined, another door opens to Cyclo/RFL. In fact, a CHMP no is a huge step in favor of ultimate approval in Europe right here if there’s significant benefit. If.
0 · Reply
Aye_Sir
Aye_Sir May. 11 at 1:19 PM
$RFL lets make some $
0 · Reply
Biotechnicity
Biotechnicity May. 11 at 5:15 AM
$RFL One sign I’m keeping an eye on is the potential sale of Zevra (ZVRA) in the very near future. I say this because tute holdings are growing and retail shares so tight that small orders ratchet up their price in AH (at that M-C no small feat). If Zevra is sold before our results come in the purchaser will have to know that there’s no competition to their profit on the near horizon. A possible study fail flag. However, if the sale of Zevra is delayed until after our results are released, it could be a sign that pending competition needs to be swallowed first. A possible checkerboard flag. In either scenario, Zevra gets sold. Not a bad buy over there. Here, 🤦
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 May. 8 at 5:24 PM
$FLNA SAVA is dead. Cyclo is now officially a better asset! It was only a matter of time.. come join $RFL before our readout this summer!!
1 · Reply
CaseOfTheYips1
CaseOfTheYips1 May. 8 at 5:21 PM
$RFL been waiting for this day… Our sp has surpassed sava! Congratulations on us being better than that dumpster fire.
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 May. 8 at 12:27 AM
$RFL One of the things I would like to see in the next six weeks is advertising for production and commercialization positions. Maybe a few sales people. That would be a good indicator that they have high confidence. If anybody can monitor their employment page, that would be helpful.
1 · Reply
Biotechnicity
Biotechnicity May. 7 at 6:04 PM
$RFL According to StockTwits own summation, Zevra is reporting that MIPLYFFA is causing “hypersensitivity reactions” (a known issue in previous studies regarding breathing through the nose). The stock is down 6% and the door to Cyclo opens wider while the jump height on P-3 success expands higher.
0 · Reply
st0ney
st0ney May. 7 at 5:10 PM
$RFL I’m down 95% in this and won’t ever recovery my money
1 · Reply
Aye_Sir
Aye_Sir May. 7 at 12:02 PM
$RFL Is Mo still here?
1 · Reply
CaseOfTheYips1
CaseOfTheYips1 May. 6 at 7:31 PM
$RFL would love to see $1.45 hit and stick… been on life support too long..
0 · Reply
FullTrust
FullTrust May. 6 at 3:34 PM
$AKBA $RFL $BIYA $SDOT Take a deeper look if you’ve been following along akebians Sdot taking former lows, great in future if it follows akba playbook off .241 low Biya taking lower range, hopefully akba can take some higher ranges from biya John hopefully has a never looking back generational catalyst for us
0 · Reply
FullTrust
FullTrust May. 6 at 3:24 PM
$AKBA $RFL 1.52 super filler
0 · Reply
Doozio
Doozio May. 6 at 12:37 AM
$RFL ONTO 🐒🍌🧠⏰♾️?
0 · Reply
Biotechnicity
Biotechnicity May. 5 at 5:18 PM
$RFL 🤣 brings added meaning to the expression: you got fined. Scott or Randy it’s always a dandy.
1 · Reply
Biotechnicity
Biotechnicity May. 5 at 1:18 PM
$RFL all of these companies soaking retail while swimming in place until the collapse. Just pathetic!
0 · Reply
sg44
sg44 May. 4 at 10:16 PM
$RFL apart from trial results DAY another very important date for our little baby stock is October 30. If the market cap is high enough we're IN and all institutions will be forced to BUY. Because of this I don't expect readout soon maybe later in September.
1 · Reply
Biotechnicity
Biotechnicity May. 4 at 8:06 PM
$RFL man these p-3 trials are expensive to run! I had projected about $100M but Cyclo may have exceeded that. Anyone know the actual numbers?
0 · Reply
History101
History101 May. 1 at 4:23 AM
$RFL 1,741 watching 4/30/2026
0 · Reply
Biotechnicity
Biotechnicity Apr. 30 at 7:56 PM
$RFL 7-8x the normal volume.
0 · Reply